Evidence mapPaperPMID 29139080Full record

ReviewDiabetes therapy : research, treatment and education of diabetes and related disorders2018

A Review of Insulin Resistance in Type 1 Diabetes: Is There a Place for Adjunctive Metformin?

Gagan Priya, Sanjay Kalra

3 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04133922 early_phase1withdrawnstarted 2019, after this paper: background citation

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

Ran2019Enrolled0Registered outcomes5Posted comparisons0ConditionsInsulin Sensitivity/Resistance, Type 1 DiabetesArmsDextrose 20 % in Water, GLP-1, Insulin
Open the trial in the graph
NCT04730882 completednot on this mapstarted 2021, after this paper: background citation

Effect of Postprandial Hyperglycemia on Vasculature in Type 1 Diabetes and Healthy Adults

TypeobservationalSponsorUniversity of VirginiaRan2021 to 2024Enrolled36ConditionsType 1 Diabetes, Hyperglycemia, PostprandialArmsMixed Meal
NCT05653518 narecruitingnot on this mapstarted 2023, after this paper: background citation

Using Closed-Loop Artificial Pancreas Technology to Reduce Glycemic Variability and Subsequently Improve Cardiovascular Health in Type 1 Diabetes

TypeinterventionalSponsorUniversity of VirginiaRan2023 to 2027Enrolled40ConditionsType 1 DiabetesArmsTandem t:slim X2 with Control-IQ Technology, Sensor augmented pump (SAP) therapy
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Gagan PriyaFortis Hospital, Mohali, India. gagan.priya@fortishealthcare.com.ORCID http://orcid.org/0000-0001-7236-2981
Sanjay KalraBharti Hospital, Karnal, India.
Bharti Hospital · INFortis Healthcare · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a rising trend of overweight and obesity among individuals with type 1 diabetes. This is often associated with insulin resistance, increased insulin dose requirements and poor glycemic control. Insulin resistance is also seen during puberty and is strongly related to increased risk of cardiovascular disease. The role of metformin as an adjunct to ongoing intensive insulin therapy in type 1 diabetics has been evaluated in several randomized trials, including the recently concluded T1D Exchange Network trial in adolescents and the REMOVAL trial in adults. Metformin reduces the insulin dose requirement, insulin-induced weight gain, and total and LDL cholesterol, but results in an increased risk of gastrointestinal adverse effects and a minor increase in the risk of hypoglycemia. In addition, metformin has been shown to reduce maximal carotid intima media thickness and therefore may extend cardioprotective benefits in type 1 diabetes. The role of metformin as adjunctive therapy in type 1 diabetes needs to be explored further in outcome trials.

Indexed as

Adjunctive therapyInsulin resistanceMetforminOverweight and obesityType 1 diabetes

Identifiers

PMID29139080
PMCPMC5801219
OpenAlexW2770872625

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.